Jan Skvarka

Dr. Jan Skvarka is an accomplished life sciences executive with decades of operational, strategic, and financial experience. Jan currently serves as the Executive Chairman of GentiBio, Inc. and DEM BioPharma, Inc. Previously, Jan was the President and Chief Executive Officer of Trillium Therapeutics, Inc. (Nasdaq: TRIL), a clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, and took the company from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. Before Trillium, Jan served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, and a leading partner in the healthcare practice of Bain & Company. Jan holds an M.B.A. from Harvard Business School and a Ph.D. in Economics from the University of Economics in Slovakia.